Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 5Breast 5Lymphoid 4Gynecologic 4Other solid neoplasm 3CNS 3Tumor-Agnostic 2Plasma cell 2Genitourinary 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ridaforolimus × Tumor-Agnostic × Clear all
NCT00694083 2024-05-21

Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT00874731 2019-05-06

MK-8669-037

Merck Sharp & Dohme LLC

Phase 1 Completed
23 enrolled 14 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡